The Hematology Podcast Sweden

Dr Mattsson and Dr Carsten Niemann, PhD, Clinical Ass. Prof. and Head of the CLL Research Laboratory at Rigshospitalet in Copenhagen, Denmark, discuss treatment considerations in CLL patients with comorbidities. This episode addresses questions such as; What to consider in patients who have high risk of infection, cardiovascular diseases, renal impairment and secondary primary mali

Dr Mattsson and Dr Carsten Niemann, PhD, Clinical Ass. Prof. and Head of the CLL Research Laboratory at Rigshospitalet in Copenhagen, Denmark, discuss treatment considerations in CLL patients with comorbidities. This episode addresses questions such as; What to consider in patients who have high risk of infection, cardiovascular diseases, renal impairment and secondary primary mali

Cardiovascular risk management in CLL In this podcast series of 2 episodes you will learn more about practical implications of cardiovascular risk and manifest cardiovascular disease when treating CLL. The discussions are led by Dr Mattias Mattsson, Senior consultant in Hematology, Hematology Department, Uppsala University Hospital, Sweden. Episode: Cardiovascular risk managemen

Episode: Cytogenetics in CLL – The role of TP53 Dr Rosenquist and Dr Sarka Pavlova, an expert on TP53 aberrations, from the Masaryk University and University Hospital Brno, Brno, Czech Republic discuss one of the most important markers in CLL, TP53. The episode addresses questions such as; What do we mean with a TP53 aberration? How do we detect TP53 alterations? And what is the

Dr Rosenquist and Dr Paolo Ghia an expert on IGHV from the Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milano, Italy, discuss the impact of IGHV status in CLL. The episode addresses questions such as; What do we mean by unmutated or mutated IGHV? How do we detect IGHV mutational status? And what is the clinical impact of IGHV mutational status for patients with

Dr Rosenquist and Dr Panagiotis Baliakas, a true expert on complex karyotype from the Department of Clinical Genetics, Uppsala University Hospital, Sweden discuss the importance of a complex karyotype for patient management and clinical decision making in CLL. The episode addresses questions such as; What is a complex karyotype? What methods should we use to detect a complex karyot

This episode deep-dives into immune responses of hematological patients, with a special focus on the most high-risk patients within this group. What do we know with regards to antibody responses in these patients? How is it measured and interpreted? Where are the gaps in terms of interpretation and clinical decision making based on antibody responses in CLL patients/hematological p

In this episode we highlight the issues that immunocompromised patients are/will be facing in light of COVID-19. The episodes identify the patient population(s) most at risk for severe infection and hospitalization or death. Also, deep diving within the hematological patients, identifying who are the most at risk and why? Which unmet needs are there for these patients today in the